- Home
- DXC vs SRPT Comparison
DXC vs SRPT Comparison
Compare DXC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | SRPT |
|---|---|---|
| Founded | 1959 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | DXC | SRPT |
|---|---|---|
| Price | $15.20 | $18.50 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 28 |
| Target Price | $15.33 | ★ $25.76 |
| AVG Volume (30 Days) | 2.2M | ★ 3.2M |
| Earning Date | 01-29-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $12,683,000,000.00 | $2,413,715,000.00 |
| Revenue This Year | N/A | $14.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.11 | ★ N/A |
| Revenue Growth | N/A | ★ 47.15 |
| 52 Week Low | $11.82 | $10.42 |
| 52 Week High | $23.75 | $120.05 |
Technical Indicators
Market Signals| Indicator | DXC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 36.74 |
| Support Level | $13.41 | $16.90 |
| Resistance Level | $15.50 | $21.36 |
| Average True Range (ATR) | 0.76 | 1.39 |
| MACD | -0.07 | -0.43 |
| Stochastic Oscillator | 67.70 | 15.99 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.